Blog

Citrus Oncology is part of the 14 startups selected for the 2025 CancerX Accelerator

Citrus Oncology/Facebook

Feb 22, 2025, 04:12

Citrus Oncology is part of the 14 startups selected for the 2025 CancerX Accelerator

Citrus Oncology shared a post on LinkedIn by CancerX, adding:

“Citrus Oncology is part of the 14 startups selected globally for the 2025 CancerX Accelerator.

We are excited to roll up our sleeves with our partner organizations to create high-value – high-impact care for our cancer thrivers through scalable AI-driven clinical decision tools creating fast access care for co-morbidities and organ-specific toxicities delivered by US Board Certified Physicians.

Congratulations to the winners!

Find CEO, Co-founder Aabid Shariff at VIVE25 to set up a meeting to learn more.

Thank you to our amazing team!”

Quoting CancerX’s post:

“Announcing the 2025 CancerX Accelerator Cohort!

We are thrilled to introduce the 14 pioneering startups selected for the 2025 CancerX Accelerator, a national innovation platform designed to accelerate digital solutions in the fight against cancer.

These game-changing companies are tackling critical challenges in clinical research, diagnostics, treatment, clinical operations, and patient/caregiver experiences – all with the goal of reducing cancer death rates and improving lives.

These innovative companies will work closely with our Accelerator Champions (and others) to fast-track their solutions and create lasting impact.

We’re excited to see how these startups drive change, and we can’t wait to follow their journey as they work to transform the future of cancer care.

Stay tuned for updates and be part of the movement to revolutionize oncology with CancerX Accelerator!”

Citrus Oncology is part of the 14 startups selected for the 2025 CancerX Accelerator